Howe & Rusling Inc. reduced its position in Edwards Lifesciences Corp (NYSE:EW) by 7.7% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 38,472 shares of the medical research company’s stock after selling 3,198 shares during the period. Howe & Rusling Inc.’s holdings in Edwards Lifesciences Corp were worth $4,205,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. ETF Managers Group LLC purchased a new position in Edwards Lifesciences Corp in the 2nd quarter worth approximately $112,000. Shine Investment Advisory Services Inc. purchased a new stake in Edwards Lifesciences Corp during the 2nd quarter valued at $126,000. Cornerstone Advisors Inc. raised its stake in Edwards Lifesciences Corp by 25.1% during the 2nd quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after buying an additional 219 shares during the last quarter. Alexandria Capital LLC raised its stake in Edwards Lifesciences Corp by 1.7% during the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after buying an additional 19 shares during the last quarter. Finally, MPS Loria Financial Planners LLC purchased a new stake in Edwards Lifesciences Corp during the 2nd quarter valued at $140,000. Institutional investors own 81.90% of the company’s stock.

WARNING: This news story was originally published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.dailypolitical.com/2017/10/20/edwards-lifesciences-corp-ew-position-trimmed-by-howe-rusling-inc.html.

Shares of Edwards Lifesciences Corp (NYSE EW) traded up 0.94% on Friday, reaching $113.08. 1,127,690 shares of the company traded hands. Edwards Lifesciences Corp has a 1-year low of $81.12 and a 1-year high of $121.45. The company has a 50-day moving average of $111.17 and a 200-day moving average of $111.78. The stock has a market capitalization of $23.88 billion, a price-to-earnings ratio of 34.30 and a beta of 0.62.

Edwards Lifesciences Corp (NYSE:EW) last released its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.20. Edwards Lifesciences Corp had a net margin of 22.11% and a return on equity of 26.27%. The company had revenue of $842.00 million during the quarter, compared to analysts’ expectations of $839.16 million. During the same quarter in the previous year, the company earned $0.76 earnings per share. The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. Analysts anticipate that Edwards Lifesciences Corp will post $3.78 earnings per share for the current fiscal year.

In other news, VP Catherine M. Szyman sold 4,681 shares of the business’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $115.78, for a total transaction of $541,966.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the business’s stock in a transaction dated Friday, July 28th. The stock was sold at an average price of $114.68, for a total transaction of $607,804.00. The disclosure for this sale can be found here. Insiders sold 201,161 shares of company stock valued at $22,826,072 in the last ninety days. 2.13% of the stock is owned by corporate insiders.

EW has been the subject of a number of research reports. BidaskClub upgraded shares of Edwards Lifesciences Corp from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 22nd. Canaccord Genuity reiterated a “buy” rating and set a $150.00 target price on shares of Edwards Lifesciences Corp in a research note on Wednesday, June 28th. Jefferies Group LLC reiterated a “buy” rating and set a $115.00 target price on shares of Edwards Lifesciences Corp in a research note on Friday, June 30th. SunTrust Banks, Inc. boosted their target price on shares of Edwards Lifesciences Corp to $14.00 and gave the company a “buy” rating in a research note on Monday, July 17th. Finally, Zacks Investment Research lowered shares of Edwards Lifesciences Corp from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 17th. Seven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $120.75.

Edwards Lifesciences Corp Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corp (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp and related companies with MarketBeat.com's FREE daily email newsletter.